Harrow Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. (HROW) on October 7, 2022. The filing addresses the termination of a material definitive agreement between the Company's subsidiary, ImprimisRx, LLC, and EyePoint Pharmaceuticals, Inc. regarding the commercial alliance for the product Dexycu.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a contractual event rather than periodic financial performance data.
Material Changes
The primary material change is the execution of a Mutual Termination Agreement with EyePoint Pharmaceuticals, effective January 1, 2023. This decision was driven by the preliminary Hospital Outpatient Prospective Payment System (HOPPS) rule proposed by the Centers for Medicare & Medicaid Services (CMS) in July 2022, which did not extend the pass-through payment period for Dexycu beyond December 31, 2022.
Outlook, Management Commentary, and Risks
- Transition Plan: Both parties agreed to continue supporting the sale of Dexycu through the fourth quarter of 2022, maintaining effort levels consistent with the January through June 2022 period.
- Sales Targets: The required minimum quarterly sales levels for the fourth quarter of 2022 have been decreased based on Dexycu unit demand.
- Future Operations: The Commercial Alliance Agreement will formally terminate on January 1, 2023.
- Documentation: The full text of the Termination Agreement is expected to be filed as an exhibit to the Company's Annual Report on Form 10-K for the period ending December 31, 2022.
Key Facts for Investor Verification
- Verify the impact of the CMS HOPPS rule on the profitability and future sales strategy of Dexycu.
- Confirm the specific financial implications of the decreased minimum quarterly sales levels for Q4 2022.
- Review the upcoming Form 10-K filing for the full text of the Termination Agreement and any associated financial adjustments.
- Assess the Company's strategy for commercial operations post-January 1, 2023, following the termination of the alliance with EyePoint.